للمتابعة
لمحبي التدبيل
Power3 Medical Announces Issuance of New U.S. Patent for the Detection of Breast Cancer Through Analysis of Biomarkers
PR Newswire - June 29, 2005 16:08
THE WOODLANDS, Texas, June 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Power3 Medical Products, Inc. (PWRM.PK) is pleased to announce that the U.S. Patent and Trademark Office has issued Patent No. 6,855,554, for which the Company has a non-exclusive license from The University of Texas M. D. Anderson Cancer Center. This patent covers the method of discovering and detecting breast cancer through the identification of protein markers or a pattern of protein markers obtained from the application of proteomics to breast nipple aspirate fluid from women being tested for breast cancer.
A second patent application, filed jointly by M. D. Anderson and the Company, covering the proteomic techniques used in the Company's NAFTest(TM), is the subject of an exclusive license the Company has with M. D. Anderson, and is currently pending.
The Power3 NAFTest(TM) (Nipple Aspirate Fluid Test) involves generating a pattern of proteins in a sample using two-dimensional gel electrophoresis to identify differences between cancerous and non-cancerous samples from the same patient.
"Breast cancer is one of the most common fatal malignancies in women, and current state-of-the-art diagnostic alternatives -- mammograms, biopsies and physician exams -- are not succeeding in terms of early detection," said Steven Rash, chairman and CEO. "We believe the Power3 NAFTest, utilizing the proteomic analysis of breast ductal fluid, promises a viable alternative for the early detection and diagnosis of this awful disease. Moreover, we believe this patent and M. D. Anderson's research further validates our technology platform, which credibly promises to speed the diagnosis and treatment of devastating diseases such as breast cancer."
Since breast cancer usually arises from a single ductal system and exists in a pre-cancerous state for a number of years, Power3 believes that the fluid collected from individual breast ducts of the same patient holds great diagnostic promise for the identification of cancer markers.
The issuance of this new patent strengthens the Power3 portfolio in the breast cancer arena. The Company's intellectual property portfolio also includes other pending patents, provisional patent applications, research and license agreements with leading medical research institutions in the areas of cancer, drug resistance, metabolic syndrome, and neurodegenerative disease.
About Power3 Medical Products
Power3 Medical Products, http://www.Power3Medical.com, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
About The University of Texas M. D. Anderson Cancer Center
M. D. Anderson, a nonprofit institution founded in 1941, has established an international reputation as one of the world's preeminent centers for cancer patient care, research, education and prevention. A multidisciplinary approach, and dedication to translational research, education and prevention are hallmarks of M. D. Anderson, which also holds the distinction of being designated by the National Cancer Institute (NCI) as one of the first three Comprehensive Cancer Centers in the United States. It has been ranked the number one cancer center in the United States in four of the past five years by U.S. News & World Report's "America's Best Hospitals."
M. D. Anderson has provided care for more than 600,000 cancer patients since 1944 and 70,000 in the last year alone. Its faculty currently hold more NCI research grants and grant dollars than any other academic center in the United States. In 2003, nearly 1,000 new patients from outside the United States came to M. D. Anderson for care. http://www.mdanderson.org.
This press release contains "forward-looking" statements, including statements related to the outcome of certain actions being taken by the Company and the anticipated timing and nature of filings with the Securities and Exchange Commission. Any statements in this press release, which are not statements of historical fact, may be deemed to be forward-looking statements. Words such as "will," "expects," "anticipates," "plans," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors and uncertainties that could cause results to differ materially from those indicated by these forward-looking statements, including risks inherent in research and development activities; the ability to raise sufficient capital and obtain financing for the development activities; uncertainties associated with regulatory approvals; as well as other risks detailed from time to time in Power3's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2003, and its reports on Form 10-QSB and Form 8-K. Power3 assumes no obligation to update
لمحبي التدبيل
Power3 Medical Announces Issuance of New U.S. Patent for the Detection of Breast Cancer Through Analysis of Biomarkers
PR Newswire - June 29, 2005 16:08
THE WOODLANDS, Texas, June 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Power3 Medical Products, Inc. (PWRM.PK) is pleased to announce that the U.S. Patent and Trademark Office has issued Patent No. 6,855,554, for which the Company has a non-exclusive license from The University of Texas M. D. Anderson Cancer Center. This patent covers the method of discovering and detecting breast cancer through the identification of protein markers or a pattern of protein markers obtained from the application of proteomics to breast nipple aspirate fluid from women being tested for breast cancer.
A second patent application, filed jointly by M. D. Anderson and the Company, covering the proteomic techniques used in the Company's NAFTest(TM), is the subject of an exclusive license the Company has with M. D. Anderson, and is currently pending.
The Power3 NAFTest(TM) (Nipple Aspirate Fluid Test) involves generating a pattern of proteins in a sample using two-dimensional gel electrophoresis to identify differences between cancerous and non-cancerous samples from the same patient.
"Breast cancer is one of the most common fatal malignancies in women, and current state-of-the-art diagnostic alternatives -- mammograms, biopsies and physician exams -- are not succeeding in terms of early detection," said Steven Rash, chairman and CEO. "We believe the Power3 NAFTest, utilizing the proteomic analysis of breast ductal fluid, promises a viable alternative for the early detection and diagnosis of this awful disease. Moreover, we believe this patent and M. D. Anderson's research further validates our technology platform, which credibly promises to speed the diagnosis and treatment of devastating diseases such as breast cancer."
Since breast cancer usually arises from a single ductal system and exists in a pre-cancerous state for a number of years, Power3 believes that the fluid collected from individual breast ducts of the same patient holds great diagnostic promise for the identification of cancer markers.
The issuance of this new patent strengthens the Power3 portfolio in the breast cancer arena. The Company's intellectual property portfolio also includes other pending patents, provisional patent applications, research and license agreements with leading medical research institutions in the areas of cancer, drug resistance, metabolic syndrome, and neurodegenerative disease.
About Power3 Medical Products
Power3 Medical Products, http://www.Power3Medical.com, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
About The University of Texas M. D. Anderson Cancer Center
M. D. Anderson, a nonprofit institution founded in 1941, has established an international reputation as one of the world's preeminent centers for cancer patient care, research, education and prevention. A multidisciplinary approach, and dedication to translational research, education and prevention are hallmarks of M. D. Anderson, which also holds the distinction of being designated by the National Cancer Institute (NCI) as one of the first three Comprehensive Cancer Centers in the United States. It has been ranked the number one cancer center in the United States in four of the past five years by U.S. News & World Report's "America's Best Hospitals."
M. D. Anderson has provided care for more than 600,000 cancer patients since 1944 and 70,000 in the last year alone. Its faculty currently hold more NCI research grants and grant dollars than any other academic center in the United States. In 2003, nearly 1,000 new patients from outside the United States came to M. D. Anderson for care. http://www.mdanderson.org.
This press release contains "forward-looking" statements, including statements related to the outcome of certain actions being taken by the Company and the anticipated timing and nature of filings with the Securities and Exchange Commission. Any statements in this press release, which are not statements of historical fact, may be deemed to be forward-looking statements. Words such as "will," "expects," "anticipates," "plans," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors and uncertainties that could cause results to differ materially from those indicated by these forward-looking statements, including risks inherent in research and development activities; the ability to raise sufficient capital and obtain financing for the development activities; uncertainties associated with regulatory approvals; as well as other risks detailed from time to time in Power3's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2003, and its reports on Form 10-QSB and Form 8-K. Power3 assumes no obligation to update
